Lenograstim
Also known as: G-CSF (CHO-derived), Granocyte, Granulokine, LEN, Lenograstim, rHuG-CSF (glycosylated), rHuG‑CSF
Source Lenograstim at Peptiology
Save 10% with code PEPTI-BOSSRABBIT-10
Tapping Shop Now & Save 10% copies your 10% off code PEPTI-BOSSRABBIT-10 to your clipboard. Paste it at the Peptiology checkout to claim the discount.
Summary
Lenograstim is a glycosylated recombinant human G‑CSF produced in CHO cells, used to accelerate neutrophil recovery after chemotherapy or bone‑marrow transplantation.
Mechanism of Action
Binds the G‑CSF receptor on hematopoietic progenitor cells, activating JAK/STAT signaling and promoting proliferation, differentiation and survival of neutrophil precursors.
Routes of Administration
Goals & Uses
- Prevention of chemotherapy‑induced neutropeniaOncology Supportive CareHigh
- Reduction of chemotherapy-induced neutropenia durationHematologic SupportHigh
- Accelerated neutrophil recovery after bone‑marrow transplantHematologyModerate
- Accelerating neutrophil recovery post bone marrow transplantTransplantation SupportHigh
- Treatment of severe chronic neutropeniaHematologic DisorderModerate
- Prevention of infections in neutropenic patientsInfection ProphylaxisHigh
- Mobilization of peripheral blood progenitor cells (PBPC)Stem Cell TransplantationHigh
Contraindications
- Myeloid malignancies (AML, CML) not receiving cytotoxic therapyOncologicHigh
- Hypersensitivity to lenograstim or any excipientAllergyHigh
- Active malignant disease (solid tumors)OncologyModerate
- Hypersensitivity to lenograstim or E. coli-derived proteinsAllergy/ImmunologicHigh
- Concomitant cytotoxic chemotherapy or radiotherapy (within 24 hours)Drug Interaction / TimingHigh
Adverse Effects
- Splenomegaly / splenic ruptureOrgan ToxicityUncommon
- Bone painMusculoskeletalCommon
- Injection site reactionsLocalCommon
- LeukocytosisHematologicCommon
- ThrombocytopeniaHematologicUncommonLow platelet count
- Pulmonary adverse events (ARDS, interstitial pneumonia)RespiratoryRare
- Allergic reaction / anaphylaxisImmuneRare
- Splenic ruptureGastrointestinal/HematologicRare
- Injection‑site reactionLocalCommon
- Bone pain / musculoskeletal painMusculoskeletalCommon
Drug Interactions
- Cytotoxic chemotherapy agentsLow
- BleomycinModerate
- CorticosteroidsLow
- LithiumLow
Population Constraints
- Pediatric patientsAgeRelative
- Patients with sickle cell diseaseHematologic DisorderRelative
- Patients with pre-existing myeloid disordersOncologicRelative
- Pregnant womenReproductiveRelative
- Pediatric patients (<2 years)AgeRelative
Regulatory Status
- European UnionApprovedApproved: Chemotherapy‑induced neutropenia, Neutropenia after bone‑marrow transplantationMarketing authorization holder: Chiesi Farmaceutici.
- United StatesUnapprovedFDA has not approved lenograstim; filgrastim is the approved G‑CSF.
- United KingdomApprovedApproved: Chemotherapy‑induced neutropenia, Post‑transplant neutropeniaApproved via EU pathway post‑Brexit.
Approved for clinical use in the European Union and several other jurisdictions; not approved by the US FDA (filgrastim is the US‑approved counterpart).
Evidence & Sources
No sources recorded yet.
Frequently Asked Questions
What is Lenograstim?
Lenograstim is a glycosylated recombinant human G‑CSF produced in CHO cells, used to accelerate neutrophil recovery after chemotherapy or bone‑marrow transplantation.
What is Lenograstim used for?
Lenograstim is educationally associated with: Prevention of chemotherapy‑induced neutropenia, Reduction of chemotherapy-induced neutropenia duration, Accelerated neutrophil recovery after bone‑marrow transplant, Accelerating neutrophil recovery post bone marrow transplant, Treatment of severe chronic neutropenia, Prevention of infections in neutropenic patients, Mobilization of peripheral blood progenitor cells (PBPC). Educational only — not medical advice.
How is Lenograstim administered?
Recorded routes of administration: Intravenous, Subcutaneous.
What are the potential side effects of Lenograstim?
Reported adverse effects include: Splenomegaly / splenic rupture, Bone pain, Injection site reactions, Leukocytosis, Thrombocytopenia, Pulmonary adverse events (ARDS, interstitial pneumonia), Allergic reaction / anaphylaxis, Splenic rupture, Injection‑site reaction, Bone pain / musculoskeletal pain. This list is not exhaustive — consult a qualified clinician.
Who should avoid Lenograstim?
Recorded contraindications: Myeloid malignancies (AML, CML) not receiving cytotoxic therapy, Hypersensitivity to lenograstim or any excipient, Active malignant disease (solid tumors), Hypersensitivity to lenograstim or E. coli-derived proteins, Concomitant cytotoxic chemotherapy or radiotherapy (within 24 hours). Consult a qualified clinician before use.